Healthcare AI startup Promedius recently announced a partnership agreement with the International Osteoporosis Foundation (IOF). The agreement was signed simultaneously with Promedius' participation in the 2024 World Osteoporosis Congress in London, England last week. It marks a significant milestone in the company's global expansion and highlights the achievements of Korean medical AI technology in the field of osteoporosis globally.

As an official sponsor of the IOF, Promedius will be eligible to participate in the Committee of Corporate Advisors (CCA) and will conduct various activities for the prevention and treatment of osteoporosis, including participation in Scientific Working Groups. The CCA is a forum of companies from various industries with the shared goal of improving bone and musculoskeletal health; it includes world-renowned pharmaceutical and biotechnology companies such as Amgen and Theramex.

IOF is the world's largest non-profit organization in the field of osteoporosis, and through this partnership agreement, Promedius will introduce Korean AI technology to the world and accelerate collaboration in research and clinical applications focused on early detection and prevention of osteoporosis. Osteoporosis is a largely asymptomatic disease, and the key is to identify patients before a fracture occurs. To this end, Promedius will actively contribute to the achievement of important milestones, such as the creation of international standardized guidelines for osteoporosis diagnosis, by regularly participating in discussions with academic societies and companies.

Dr. Phillipe Halbout, President of the IOF, said: "Promedius is the first Korean company to participate in the World Osteoporosis Society and join the IOF CCA. This will allow us to build bridges with bone health societies in Korea in the future," said Dr. Philippe Halbout, President of the IOF.

Promedius will also participate as a Platinum Sponsor at the Asia Pacific Singapore Osteoporosis and Other Metabolic Bone Disorders Summit (APCO) in Singapore from May 17-19, where it will host a luncheon symposium on the topic of “Opportunity Screening for Osteoporosis Using Artificial Intelligence Solutions.”